Related Experiment Video

Updated: Nov 8, 2025

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.2K

Novel small molecular inhibitor of Pit-Oct-Unc transcription factor 1 suppresses hepatocellular carcinoma cell

Yue Wang1, Shuo Liu1, Qin Chen1

  • 1Department of Pharmacy, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Number 44 Xiaoheyan Road, Dadong District, Shenyang 110042, Liaoning Province, People's Republic of China.

Life Sciences
|April 23, 2021
PubMed

Insights

A new drug, SMIO-1, targets the OCT1 (Pit-Oct-Unc transcription factor 1) protein, which is overexpressed in liver cancer. This drug shows promise in treating hepatocellular carcinoma (HCC) by inhibiting cancer cell growth and spread.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Hepatocellular carcinoma (HCC) is a leading cause of cancer death in China, often linked to hepatitis infections.
  • Current treatments like sorafenib have limited efficacy for advanced HCC.

Purpose of the Study:

  • Investigate Pit-Oct-Unc transcription factor 1 (OCT1/POU2F1) as a therapeutic target for HCC.
  • Design and evaluate a novel small molecule inhibitor of OCT1 (SMIO-1) for HCC treatment.

Main Methods:

  • Analyzed OCT1 expression in HCC tissues and correlated it with patient prognosis.
  • Utilized molecular docking to predict SMIO-1 interaction with OCT1.
  • Confirmed SMIO-1 and OCT1 interaction using OCT1 point mutation.
  • Assessed SMIO-1's effect on HCC cell proliferation and metastasis in vitro.

Main Results:

  • Elevated OCT1 expression in HCC tissues compared to non-tumor tissues.
  • Higher OCT1 levels correlated with poorer prognosis in advanced HCC patients on sorafenib.
  • SMIO-1 effectively repressed OCT1 transcriptional activity by disrupting cofactor interactions.
  • SMIO-1 inhibited HCC cell proliferation and metastasis, and downregulated related genes.

Conclusions:

  • OCT1 is a potential therapeutic target for hepatocellular carcinoma.
  • The novel inhibitor SMIO-1 demonstrates significant therapeutic potential against HCC by targeting OCT1.
Keywords:
Hepatocellular carcinomaPit-Oct-Unc transcription factor 1Proliferation and metastasisProtein interactionSmall molecular inhibitor of OCT1

More Related Videos

In Vitro Cultivation Techniques for Modeling Liver Organogenesis, Building Assembloids, and Designing Synthetic Tissues using Human Cell Lines08:50

In Vitro Cultivation Techniques for Modeling Liver Organogenesis, Building Assembloids, and Designing Synthetic Tissues using Human Cell Lines

Published on: April 18, 2025

673
Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System05:55

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System

Published on: December 21, 2019

6.9K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.2K
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
10.3K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.4K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
37.2K